FHTX Q1 2023 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+35.4% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$33M-627.6% margin

Net Income

-$30M-574.3% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

+26.9%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$32M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$373M

Total Liabilities

$397M

Stockholders' Equity

-$25M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$4M	+35.4%
Gross Profit	$5M	-$21M	+125.8%
Operating Income	-$33M	-$28M	-19.8%
Net Income	-$30M	-$27M	-13.3%